Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
A team of researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) have created an AI that’s capable of automatically deciphering long lost languages, even without any ...
Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...
Bunzz, a Singapore-based web3×LLM tech web3-startup, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating Smart ...
Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics and expands TAM with presence in 7 of the 10 most common cancers “Bringing Decipher into the Veracyte family ...
Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Decipher's prostate cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback